Laudanosine (Isoquinoline Alkaloid · CNS Stimulant · Forensic Reference)
| Compound | Laudanosine (1-Benzyl-1,2,3,4-tetrahydroisoquinoline; N-Methyl-tetrahydropapaverine) |
| Class | Alkaloid — Isoquinoline (Benzylisoquinoline) |
| CAS | 2688-77-9 |
| Molecular formula | C₂₁H₂₇NO₄ |
| Primary sources | Papaver somniferum (opium poppy) — trace constituent of crude opium |
| Plant part | Capsule latex (opium) |
| Claim strength | Emerging |
| Key applications | Forensic chemistry; anaesthesia research; CNS stimulant reference; informational-only |
| Buy from Herbuno | Informational reference — see HerbIQ Compound Index → |
Name origin: Laudanosine is named for its first isolation from laudanum — the historical opium tincture that was the primary analgesic preparation of the 17th–19th centuries. It is the N-methyl, fully reduced (tetrahydro) derivative of papaverine, classifying it as a benzyltetrahydroisoquinoline (BTIQ) alkaloid. Traditional use: Laudanosine is not a traditional medicine constituent in its own right — it occurs as a minor trace alkaloid in crude opium alongside the pharmacologically dominant morphine, codeine, papaverine, and noscapine. Its significance in traditional pharmacopeias is nil; its significance in modern medicine is as a metabolite. Research trajectory: Laudanosine gained clinical pharmacological relevance as a metabolite of the neuromuscular blocking agents atracurium and cisatracurium — two widely used anaesthetic drugs whose Hofmann elimination produces laudanosine as a by-product in patients. At high plasma concentrations (not achievable through natural opium consumption), laudanosine produces CNS stimulation including seizures in animal models — a concern that drove the development of cisatracurium, which produces less laudanosine per effective dose. Safety context: Laudanosine from natural opium sources is present at toxicologically insignificant concentrations; the clinical concern arises only from intravenous atracurium/cisatracurium infusion in ICU patients. It is not a controlled substance itself but derives from controlled plant material.
Pharmacological Profile of Laudanosine
CNS stimulant activity: Laudanosine is a glycine receptor and GABA-A receptor antagonist with weak affinity for muscarinic receptors. In rodent models at IV doses of 5–20 mg/kg, laudanosine produces dose-dependent CNS arousal, tremor, and generalised tonic-clonic seizures. The seizure threshold is well above any concentrations achievable via oral opium-related exposure. Claim strength: Emerging (animal data only).
Anaesthesia metabolite concern: Atracurium (Tracrium) undergoes spontaneous Hofmann elimination at physiological pH and temperature, generating laudanosine and a monoquaternary acrylate. In patients receiving prolonged atracurium infusion (ICU sedation for days), laudanosine accumulates — particularly in renal or hepatic failure. Cisatracurium was developed to address this: it is a single stereoisomer with greater potency, requiring lower doses and generating proportionally less laudanosine. Claim strength: High (pharmaceutical pharmacokinetic context).
Forensic chemistry: Laudanosine is one of several minor alkaloids profiled in illicit opium and heroin forensic analysis, used for geographic origin determination and source plant authentication. Its ratio to papaverine and other BTIQs is characteristic of Papaver somniferum from specific cultivation regions. Claim strength: Moderate (analytical chemistry).
Biosynthetic interest: As a benzyltetrahydroisoquinoline, laudanosine sits in the biosynthetic family upstream of morphine, codeine, papaverine, and berberine — making it relevant to metabolic engineering research aimed at microbial or plant biosynthesis of pharmaceutical opioids. Claim strength: Emerging.
This compound is documented for research and formulator education purposes. For commercially available botanical ingredients, explore the HerbIQ Compound Index →
Regulatory and Formulator Context
Laudanosine is not a scheduled controlled substance in most jurisdictions (unlike morphine, codeine, or thebaine), but its source material — Papaver somniferum latex — is subject to international narcotic plant controls under the 1961 Single Convention. Isolated laudanosine in laboratory research contexts does not carry independent scheduling.
There is no supplement or nutraceutical application for laudanosine. Its pharmacological activity (CNS excitation, seizure risk at high doses) is not relevant to dietary supplement formulation, and its botanical source is a controlled narcotic plant. This page serves as a formulator reference only.
The clinical significance of laudanosine accumulation in anaesthesia is managed by drug selection (cisatracurium preferred over atracurium in prolonged infusion) and routine anaesthetic monitoring. No interventional supplement approach to laudanosine pharmacology is established or appropriate.
Formulators and researchers requiring information on Papaver alkaloid chemistry for pharmaceutical process development or forensic reference purposes should consult primary analytical chemistry literature and appropriate regulatory frameworks.
Frequently Asked Questions — Laudanosine
How does laudanosine relate to atracurium used in anaesthesia?
Atracurium undergoes spontaneous Hofmann elimination at body temperature and pH 7.4, producing laudanosine as a metabolite. In ICU patients on prolonged atracurium infusions (days to weeks), laudanosine accumulates in plasma. At high concentrations demonstrated in animal studies, laudanosine causes CNS excitation and seizures. This concern drove clinical preference for cisatracurium, which requires lower doses and generates less laudanosine.
Is laudanosine a controlled substance?
Laudanosine itself is not scheduled under major controlled substances frameworks (DEA, INCB). However, it is a constituent of Papaver somniferum latex, which is subject to narcotic plant controls internationally. Research-grade laudanosine is commercially available for analytical standards purposes without independent scheduling restrictions in most markets.
What is the forensic significance of laudanosine in opium analysis?
Laudanosine is one of the minor alkaloids profiled in opium forensic analysis alongside papaverine, narceine, and rhoeadine. Its relative concentration compared to other benzylisoquinolines varies by P. somniferum variety and geographic origin, contributing to chemotypic fingerprinting used in drug trafficking source analysis.
Why is laudanosine included in the HerbIQ Compound Index?
HerbIQ documents all pharmacologically significant plant alkaloids as a comprehensive formulator and researcher reference. Laudanosine is included for completeness of the Papaver alkaloid series and its anaesthesia pharmacology relevance. The informational-only designation clearly signals no sourcing or supplement intent from Herbuno.
Related compounds: Laudanine, Neopine, Reticuline, Papaverine
Claim-strength scale – High = multiple human RCTs; Moderate = limited trials or strong preclinical convergence; Emerging = early-stage lab or animal data.
← HerbIQ Compound Index · HerbIQ P02: Extraction · HerbIQ P03: Delivery